Understanding the Immunology of Multiple Sclerosis
|
|
- Mitchell Osborne
- 5 years ago
- Views:
Transcription
1 Understanding the Immunology of Multiple Sclerosis Kathleen Costello, MS, ANP-BC, MSCN, and Anne Gocke, PhD Johns Hopkins Multiple Sclerosis Center and Johns Hopkins University School of Medicine, Baltimore, Maryland Abstract A growing body of evidence has accumulated over the past 25 years that multiple sclerosis (MS) is an immune-mediated disease characterized by inflammatory and degenerative processes that damage the central nervous system. Knowledge of the immunology of MS has led to the therapeutic arsenal of agents now available to fight the disease, and additional immunopathologic mechanisms currently being elucidated certainly will influence future therapeutic directions. In a course for nurses and other nonimmunologists offered at the joint 28 th Annual Meeting of the Consortium of MS Centers (CMSC) and the 19 th Annual Meeting of the Americas Committee for Treatment and Research in MS (ACTRIMS), speakers described the normal immune response, provided a basic understanding of the immunopathology of MS, discussed the mechanisms of action of current disease-modifying therapies, and delved into more recently discovered inflammatory and degenerative mechanisms involved in relapsing and progressive forms of the disease. M ultiple sclerosis (MS) is an inflammatory-mediated neurodegenerative disease of the central nervous system (CNS). Its etiology is unknown; however, a variety of immune cells including B cells, T cells, monocytes, macrophages, microglia, dendritic cells, and others all play a role in its pathogenesis. The CNS once was considered to be an immune-privileged site. Currently, it is thought that baseline immune surveillance in the CNS is important for maintaining homeostasis and protecting the CNS from opportunistic infection. MS results from an abnormal and dysregulated CNS immune response that causes damage and destruction of myelin, oligodendrocytes, and axons. During a course held at the joint 28 th Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and the 19 th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), experts discussed immunology as it relates to MS, medical therapies currently being used and on the horizon, causes of CNS inflammation, and differences between relapsing and progressive forms of the disease. n HOW DOES THE NORMAL IMMUNE SYSTEM WORK? Based on a presentation by Kathleen Costello, MS, ANP-BC, MSCN, Johns Hopkins Multiple Sclerosis Center, Johns Hopkins Medicine, Baltimore, Maryland. The normal immune system protects against infectious threats; responds to active infections; and, through immunologic regulatory mechanisms, prevents development of autoimmune conditions. Specificity, diversity, memory, and the ability to distinguish between the body s own cells ( self ) and foreign cells ( non-self ) are important properties of the immune system. The body has a number of natural defense barriers (skin, body fluids, lung and gut cilia, and mucus) that work to keep infectious threats out of the system. However, a breech in the barrier system provokes the cellular activity of the innate immune system. Through a complex communication system, the innate immune system cells become activated when a threat is identified. Neutrophils, monocytes, macrophages and, natural killer (NK) cells are important members of the innate immune system. These cells can recognize broad classes of pathogens and, in many cases, are able to eradicate them. When an infection requires additional immunologic intervention, the adaptive immune system, staffed by T and B cells, is called to action. Various messengers signal these cells to begin to defend the body (Figure 1). Cell-surface molecules, including the major histocompatibility complex (MHC), are critical to activation of the adaptive immune system, as are co-stimulatory molecules that allow for full activation of adaptive immune cells. Adhesion molecules on blood vessels and cell walls are upregulated, allowing cellular movement from the bloodstream to the site of infection in tissues. Cells That Defend Us Macrophages are the body s sentries, lying in wait for invasion by pathogens. These cells are found under the skin, in the lungs, and in the tissues surrounding the gut. In addition, they collect waste products and minimize cellular debris from Ms. Costello is an Associate Vice President of the Advocacy, Services and Research Department of the National Multiple Sclerosis Society; an Adult Nurse Practitioner in the Johns Hopkins Multiple Sclerosis Center; and Adjunct Assistant Professor of Neurology at Johns Hopkins University School of Medicine, Baltimore, Maryland. Dr. Gocke is Assistant Professor of Neurology at Johns Hopkins University School of Medicine. 6 T H E N E U R O L O G Y R E P O R T V o l u m e 7 N u m b e r 2
2 dead cells. Receptors on the surface of macrophages recognize signals from the pathogen that stimulate a seek eat destroy mechanism. When macrophages are stimulated to seek out and destroy an invading pathogen, they send out signals called cytokines to recruit more immune system cells. Macrophages also can engulf an invader and display a piece of it on the cell surface, so it can be recognized by the adaptive immune system. Macrophages provide a strong defense, but bacteria multiply quickly. Rather than acting alone, macrophages send out signals to attract neutrophils and monocytes from the blood to the site of infection. Neutrophils and monocytes are short-lived cells that circulate in the blood. A signal sent from the macrophage allows them to move quickly to the site of infection. Signals from the tissue cause upregulation of surface molecules that allows neutrophil entry into tissue at the infection site. Neutrophils. Along with macrophages, the chemokines interleukin (IL)-1 and tumor necrosis factor (TNF) call neutrophils to action. Complex communication lines cause the neutrophil to slow down, sense the location of infection, adhere to the blood vessel, and migrate from the blood vessel into the tissue. Monocytes circulate for several days and finally leave the blood and enter tissues, where they mature into macrophages. These powerful phagocytes stimulate repair mechanisms and produce IL-1, TNF, and reactive oxygen species (especially hydrogen peroxide) when they are activated. Monocytes also act as antigen-presenting cells (APCs) for lymphocyte functioning in adaptive immunity, and they become further stimulated by the mechanisms of this protective mechanism. NK cells use this same mechanism to exit the circulation and migrate into tissues. Adhesion molecules are key in signaling cells that they have arrived at the correct location. NK cells mostly circulate in the blood; signals from the infection site activate them. Upregulation of adhesion molecules allows NK cells to enter the tissue at Cytokines from activated T cells Clonal expansion of activated T cells Mφ Activation of macrophages Memory T cell Naïve Act T Tcell the infection site and become killers. NK cells deliver powerful enzymes to target cells infected by viruses, which causes the cells to die, thus reducing the number of infected cells. NK cells also secrete cytokines, which help hyperactivate macrophages and prime more macrophages to participate in the killing. Complement is a series of proteins that is activated very rapidly in a coordinated and orderly way by the innate and adaptive immune systems. In innate immunity, proteins in the complement system can become active when they recognize common chemical groups on the infected cell surface. Complement can IL-12 Costimulatory molecules MHC + antigen Antigen presentation and recognition Pathogen Dendritic cells tag an invader for destruction or bore a hole in invading cells to destroy them. Antigens and Antibodies Dendritic cell Dendritic cell encounters pathogen FIGURE 1 Adaptive immunity: T-cell activation. IL-12 = interleukin-12; MHC = major histocompatibility complex; Mφ = macrophage cell. Adapted, with permission, from a slide presented by Kathleen Costello, MS, ANP-BC, MSCN, at the 2014 joint CMSC/ACTRIMS annual meeting. Pathogen Memory Bcell Memory B cell BCR Bcell B cell Activated B cell becomes effector cell (PC) or memory B cell MHC II T h T helper cell PC Antibody produced by PC Activated T helper cell stimulated by B-cell antigen presentation Macrophage Complement stimulated by antibody FIGURE 2 B-cell activation. BCR = B-cell receptor; MHC = major histocompatibility complex; Mφ = macrophage cell. Adapted, with permission, from a slide presented by Kathleen Costello, MS, ANP-BC, MSCN, at the 2014 joint CMSC/ACTRIMS annual meeting. Mφ The adaptive immune system is activated when an additional response is needed to eradicate a pathogen. These actions include cell-mediated activity involving specialized T cells known as T helper (Th) cells, including, Th 1, Th 2, and Th 17 ; and also humoral activity, involving B and T cells, antibodies, and complement. The ability of antibodies to recognize specific antigens is an important characteristic (Figure 2). Antigen recognition and binding allow antibodies to perform T H E N E U R O L O G Y R E P O R T S u m m e r
3 four important effector functions in eliminating invading pathogens: opsonization, complement activation, toxin neutralization, and blocking attachment. T- and B-Cell Interaction T cells are important players in the adaptive immune response, but they are activated only when a recognizable antigen is presented to them by a professional APC, such as a dendritic cell or a macrophage. The naïve T cell is stimulated by antigen presentation and is differentiated into various T-cell subsets, such as Th 1, Th 2, or Th 17. Th 1 differentiation occurs with IL-23 and interferon γ stimulation. Th 2 differentiation occurs with stimulation by IL-4, as with parasitic infections. Th 17 differentiation occurs with stimulation by IL-6, IL-1, and IL-23. T cells become activated and multiply based upon the antigen presented and the cellular environment, and this activation will provoke their immunologic activity. B cells, also important players in adaptive immunity, are able to recognize antigens that are in circulation and do not require the specialized antigen presentation that T cells require. B-cell clonal expansion and the production of plasma and memory cells require the help of T cells and the actions of cytokines. B cells recognize antigen in the circulation and are able to bind to the antigen and internalize it. After internal processing, a small piece or peptide of the antigen is presented on the cell surface in a groove of the MHC molecule, where an activated or memory T cell can can recognize and interact with it. This contact sends signals to the B and T cells to allow the T cells to stimulate production of receptors and cytokines and to provide a second co-stimulatory signal for B cells. Summary The immune system protects the body from pathogens and purges invasive proteins from the circulation. The normal immune system features specificity, diversity, and memory, and it can differentiate the body s own cells from foreign cells. If this system malfunctions, however, an autoimmune response may occur. n WHAT CAUSES INFLAMMATION OF THE CNS IN MS? Based on a presentation and written summary by Anne Gocke, PhD, Assistant Professor of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland. The most important determinants of permanent neurologic disability in MS are axonal damage and loss. MS is an immune-mediated inflammatory disease characterized by myelin destruction, damage to CNS-resident cells, and loss of mobility and cognition. In acute and chronic active lesions, axons commonly are preserved; macrophages that have taken up myelin debris are evident. In contrast, inactive lesions feature a loss of axons and oligodendrocytes and few macrophages. Cortical plaques, which involve the gray matter, also may be found. The antigens that are targeted in MS likely are not limited to myelin proteins. They also may include neuronal proteins and astrocytic proteins, among other unknown candidates. Genetic predisposition has been linked with mutations in cytokine receptor genes (IL2RA, IL7R) as well as HLA-DR2B. Environmental factors, including vitamin D, Epstein-Barr virus, and gut and lung immunity, also play an important role in MS susceptibility. Gender is another risk factor for development of the disease, since some 66% of affected patients are female. CD4 + T cells of the Th 1 and Th 17 lineages and cytotoxic CD8 + T cells play a pathogenic role in MS, likely due to their ability to secrete proinflammatory cytokines and recruit peripheral monocytes and B cells to MS lesions. B cells may secrete antibodies that can mediate direct damage to axons. The presence of lymphoid follicles in the meninges of some patients points toward a pathogenic role for B cells in MS. B cells also help in repair and remyelination by promoting clearance of myelin debris via opsonization. Microglia sense changes in the CNS and release cytokines and chemokines that pave the way for entry of other immune cells into the lesion site. Peripheral monocytes infiltrate the CNS and secrete proinflammatory cytokines and toxic molecules, such as nitric oxide, IL-1, IL- 6, and matrix metalloproteinases, which can directly damage oligodendrocytes and neurons. CNS Inflammation and Axonal Damage The most important determinants of permanent neurologic disability in MS patients are axonal damage and loss. Axonal damage may occur even early in the course of the disease. Several different hypotheses for a link between an aberrant inflammatory response in the CNS and axonal damage in MS have been put forth. They include: Activation of CD8 + T cells to target neurons directly; Vigorous CD4 + T-cell responses that recruit macrophages, resulting in the release of inflammatory mediators and toxic molecules; Binding of antibodies to neuronal surface antigens, followed by complement fixation or antibody-mediated phagocytosis of axons; Triggering of a program in CNS resident cells by invading immune cells, which results in secondary inflammationindependent neurodegeneration; and Indirect mechanisms, including mitochondrial dysfunction, dysregulation of ion channels, or release of glutamate or nitric oxide as a result of chronic inflammation. Summary The etiology of MS is unknown. However, the immune system is important to the development of the disease, and lesions affect both the gray and white matter. MS may begin with an invasion of the CNS by T and B cells. These events may be secondary to activation of microglia and macrophages and the local release of self or foreign antigens. 8 T H E N E U R O L O G Y R E P O R T V o l u m e 7 N u m b e r 2
4 A small number of antigens presented in the CNS may drive the highly focused, persistent acquired immune response in MS. Possible candidates include myelin or neuronal antigens and antigens from infectious agents epidemiologically associated with the disease. n HOW DISEASE-MODIFYING THERAPIES (DMTs) AFFECT THE ALTERED IMMUNE RESPONSE Based on a presentation by Scott Newsome, DO, Assistant Professor of Neurology and Director, Neurology Outpatient Services, Johns Hopkins University School of Medicine, Baltimore, Maryland. The subtypes of MS are based upon the clinical behavior of the disease over time. They include relapsing-remitting MS (RRMS), secondary-progressive MS (SPMS), primary-progressive MS (PPMS), and progressive-relapsing MS (PRMS). In untreated individuals who initially have a relapsing-remitting course to their MS, approximately 50% will develop more progressive symptoms (SPMS) after about 15 years. Over the past 25 years, increasing knowledge of the immunopathology of MS has led to the development of several different DMTs that can reduce the frequency of relapses; reduce new inflammatory activity in the CNS; and, to varying degrees, delay the accumulation of disability (Table 1). Examination of how these drugs affect patients with RRMS reflects a greater understanding of the pathways of the disease. Interferon β-1a and β-1b Interferon β-1a and β-1b are proteins that have powerful anti-inflammatory effects. Interferons reduce T-cell activation and proliferation, reduce secretion of matrix metalloproteinases that disrupt the blood-brain barrier (and thus allow fewer immune cells entry into the CNS), inhibit interferon γ release (reduces antigen presentation to T cells), and limits T-cell migration across the blood-brain barrier. In addition, recent findings suggest that interferons reduce antigen processing and antigen presentation to T cells. At low doses, these drugs may cause minor side effects, such as flu-like symptoms, TABLE 1 Currently Approved Disease-Modifying Therapies for Patients with Relapsing-Remitting Multiple Sclerosis Year Generic name (trade name) Route and frequency of administration 1993 Interferon β-1b (Betaseron) Subcutaneous injection every other day 1996 Interferon β-1a (Avonex) Intramuscular injection once a week 1996 Glatiramer acetate (Copaxone) Subcutaneous injection once a day 2000 Mitoxantrone (Novantrone) Intravenous infusion every 3 months 2002 Interferon β-1a (Rebif) Subcutaneous injection 3 times a week 2004 Natalizumab (Tysabri) Intravenous infusion once a month 2009 Interferon β-1b (Extavia) Subcutaneous injection every other day 2010 Fingolimod (Gilenya) Orally once a day 2012 Teriflunomide (Aubagio) Orally once a day 2013 Dimethyl fumarate (Tecfidera) Orally twice a day 2014 Glatiramer acetate (Copaxone) Subcutaneous injection 3 times a week 2014 Peginterferon β-1a (Plegridy) Subcutaneous injection every 14 days headache, transaminitis, and depression; major side effects include suicidal ideation, anaphylaxis, hepatic injury, blood dyscrasias, seizures, and autoimmune hepatitis. At high doses, all of these effects may be seen, although injection-site reactions and skin necrosis also may occur. Patients should be followed with complete blood cell counts with differential, liver and thyroid function tests, and interferon-neutralizing antibodies, if clinically warranted. Glatiramer Acetate Originally, the mechanism of action of glatiramer acetate was believed to involve a shift from Th 1 to Th 2 cells and a blocking of the MHC peptide antigen. More recently, treatment with glatiramer acetate has been shown to cause migration of Th 2 cells into the CNS, modification of antibody production by plasma cells, and regulation of B-cell properties. In addition, recent evidence suggest that glatiramer acetate may produce cytokine modulation, inhibition of antigen presentation to T cells, and effects on oligodendrocyte precursor cells (myelin repair). Minor side effects of glatiramer acetate include injection-site reactions and postinjection vasodilatory reactions; major side effects include lipoatrophy, skin necrosis, and anaphylaxis. No particular patient monitoring is needed. Mitoxantrone Mitoxantrone mainly is used to treat leukemia and prostate cancer. This DNA topoisomerase II inhibitor suppresses the proliferation of T and B cells and macrophages. The lifetime dose of this drug is 140 mg/m 2. Owing to its high-risk profile and the availability of other effective DMTs with fewer risks, mitoxantrone currently is used infrequently for the treatment of patients with RRMS. Use of mitoxantrone is related to nausea, vomiting, hair thinning, infections, liver dysfunction, and menstrual irregularities. Significant reported risks include cardiotoxicity, acute myelogenous leukemia, serious infections, and infertility. Patients should undergo a complete blood cell count with differential, liver function tests, echocardiography, or an echo/multigated acquisition scan while receiving mitoxantrone and even after therapy ends. Natalizumab Natalizumab, the first selective adhesion molecule inhibitor developed, is a humanized monoclonal antibody that targets the α4-integrin on the surface of lymphocytes, which facilitates the movement of white blood cells into organs. Natalizumab blocks the expression of this adhesion molecule, thus limiting the number of lymphocytes that enter the CNS. Treatment with natalizumab may cause headaches; joint pain; fatigue; and a wearing-off phenomenon, wherein patients feel a temporary recrudescence of their MS symptoms just prior to each infusion. T H E N E U R O L O G Y R E P O R T S u m m e r
5 The major risk of taking natalizumab is a severe and potentially fatal infection known as progressive multifocal leukoencephalopathy (PML), caused by reactivation of the otherwise dormant John Cunningham virus (JCV). In addition, infusion reactions, hypersensitivity reactions, and other serious infections, such as herpes zoster virus and other infections, may occur. Patients should have a complete blood cell count with differential, liver function tests, and serum JCV antibody measurements every 6 months, as well as periodic magnetic resonance imaging (MRI), and measurement of natalizumab antibodies if clinically indicated. Should PML be suspected, an MRI should be obtained to identify any new CNS activity. If it is present, a lumbar puncture may be needed to search for JCV in the cerebrospinal fluid. Fingolimod This oral medication is given daily. It is a sphingosine 1-phosphate receptor (S1PR) modulator that affects the receptors S1P1, S1P3, S1P4, and S1P5. Fingolimod functionally antagonizes S1PR blocking lymphocyte egress from secondary lymphoid organs to the peripheral blood circulation. Minor side effects include lymphopenia (lymphocyte count > 200 cells/mm 3 ) and transaminitis; major side effects include bradycardia, heart block, hypertension, risk of herpetic infections, lymphopenia (lymphocyte count < 200 cells/mm 3 ), macular edema, skin cancer, reactive airway, and posterior reversible encephalopathy syndrome. Patients should undergo cardiac monitoring with the first dose, an eye and skin examination, a complete blood cell count with differential, liver function tests, measurement of varicella IgG titers before starting the medication, and pulmonary function tests if indicated. Teriflunomide This oral medication is an active metabolite of leflunomide. It mimics pyrimidine as a DNA building block, interferes with DNA synthesis, and inhibits dihydro-orotate dehydrogenase. Use of the drug is cytostatic to proliferating B and T cells. Teriflunomide reduces T-cell proliferation and activation and production of cytokines, and it interferes with the interaction between cells and APCs. Teriflunomide may cause diarrhea, nausea, and thinning of the hair; more severe effects include transaminitis, lymphopenia, teratogenicity, latent tuberculosis, neuropathy, and hypertension. A complete blood cell count with differential and liver function tests should be done monthly for the first 6 months of therapy. In addition, patients should undergo tuberculosis screening before starting treatment with teriflunomide and a wash-out if indicated. Dimethyl Fumarate Dimethyl fumarate changes the balance of Th 1 to Th 2 cells and activates the transcription factor Nrf2 transcriptional pathway, which can reduce oxidative stress. Patients using dimethyl fumarate have experienced flushing and GI distress; in more severe cases, transaminitis and leukopenia may occur. Monitoring should include a periodic complete blood cell count with differential and liver function tests. Peginterferon β-1a Peginterferon β-1a is a chemically modified version of interferon β-1a, where polyethylene glycol has been attached to the interferon molecule, thus allowing it to remain active in the circulation for 2 4 weeks after a single subcutaneous (SC) injection. Adverse effects include injection-site reactions and flu-like symptoms. Laboratory monitoring of MS patients receiving this drug is similar to that of other interferons. Emerging Therapies Several drugs are in late stages of clinical development to treat patients with relapsing MS. Alemtuzumab targets CD52 + cells present on mature lymphocytes and depletes B and T cells. Used off-label to treat MS, it is administered over several days once a year. Side effects of alemtuzumab can be serious and may include infusion reactions, autoimmune thyroid disease, idiopathic thrombocytopenic purpura, Goodpasture s syndrome, and herpes simplex and varicella virus infections. Patients receiving alemtuzumab should undergo monthly complete blood cell counts with differential, liver function tests, and thyroid function tests. Daclizumab high-yield process targets the α subunit of the IL-2 receptor on T cells, reduces activation and proliferation of T cells, and expands CD56-bright cells that inhibit T-cell survival. It is administered monthly by SC injection. Side effects include transaminitis, autoimmune hepatitis, lymphadenopathy, rash, and alopecia universalis. Although exact monitoring still must be determined, patients should undergo liver function tests and complete blood cell counts with a differential. Ocrelizumab is a fully humanized monoclonal antibody that targets CD20 + B cells. It is given as an intravenous infusion every 6 months. Adverse effects include infusion reactions, lymphopenia, and infections. Patients should be monitored with CD19/CD20 B-cell counts. n HOW DOES PROGRESSIVE MS DIFFER FROM RELAPSING MS? Based on a presentation and written summary by Anne Gocke, PhD. Most MS patients will experience progression at some stage of their disease (Figure 3). RRMS involves unpredictable attacks that may involve permanent deficits and periods of remission. Patients with PPMS exhibit a steady increase in disability without attacks, whereas those with SPMS experience initial RRMS that suddenly is related to declines in function, although periods of remission occur. Finally, those with PRMS experience a steady decline in function and exhibit superimposed attacks. A definitive disease mechanism for progressive and relapsing MS has not been identified, although the role of environmental triggers, genetics, and other factors has been scrutinized. However, a number of interlinked pathways may contribute to the pathogenesis of the disease. PPMS Men are more likely to be affected by PPMS than by any other form of the 10 T H E N E U R O L O G Y R E P O R T V o l u m e 7 N u m b e r 2
6 disease. This form of disease progression typically begins about 10 years after the onset of RRMS. Genetic susceptibility and pathology of this disorder are similar to those of other forms of MS, and an underlying neurodegenerative problem could be involved. Meningeal infiltrates of B and T cells are particularly prominent in patients with PPMS, and lymphoid follicles associated with underlying microglia activation and cortical plaques may be evident. White-matter plaques often are neuroinflammatory at their center, but microglia, macrophages, and ongoing simmering and possibly concentrically expanding axonopathy may be found. In addition, diffuse, low-grade parenchymal inflammation has been reported. Therapeutic failures could be explained by perivascular inflammation, which often occurs without associated disruption of the blood-brain barrier. Axonal and neuronal death may result from glutamate-mediated excitotoxicity, oxidative injury, iron accumulation, and/or mitochondrial failure. Currently, a lack of full understanding about the biology of MS impedes the development of effective treatments. Clinical investigators have questions about mechanisms driving progressive disease, therapeutic options currently are limited to symptomatic treatments and physical therapy, and no animal model that accurately models this disease stage is available. Further, an important question remains is the evolution from relapsing MS to progressive MS different from that of PPMS? Pathogenesis. In progressive MS, brain damage is driven by inflammation similar to that of RRMS but with an intact blood-brain barrier. This condition starts as an inflammatory disease. However, chronic inflammation leads to neurodegeneration or disease progression independent of inflammation. This neurodegeneration might cause intact neurons to lose control over microglial activation. In the early stages of the disease, inflammation amplifies progression of primarily neurodegenerative disease. In general, PPMS is characterized by diffuse, rather than focal, inflammation and involves more prominent cortical Increasing disability demyelination, diffuse axonal injury, and, frequently, the presence of microglial nodules in the brain. RRMS Time RRMS is characterized by acute focal inflammatory lesions in the white matter. Pathologically, RRMS is associated with inflammatory demyelinating lesions in the brain and spinal cord, which herald axonal damage and loss related to the foci of inflammation. The gray matter is involved less prominently in RRMS than it is in progressive MS. Pathologic Changes Inflammation occurs at all stages of MS and consists of perivascular and parenchymal infiltrates of lymphocytes and macrophages. The initial inflammatory response in patients with RRMS mainly involves the proliferation of CD8 + T cells in active lesions, as abundant macrophages are Progressive-relapsing multiple sclerosis Steady decline in function since onset, with superimposed attacks Secondary progressive multiple sclerosis Initial relapsing-remitting multiple sclerosis followed by a sudden decline in function, with periods of remission Primary progressive multiple sclerosis Steady increase in disability without attacks Relapsing-remitting multiple sclerosis Unpredictable attacks, which may or may not leave permanent deficits, followed by periods of remission FIGURE 3 Types of multiple sclerosis. Adapted, with permission, from a slide presented by Anne Gocke, PhD, at the 2014 joint CMSC/ACTRIMS annual meeting. recruited and activated. In the secondary response, T and B cells and macrophages are recruited as a result of myelin destruction. Profound damage to the blood-brain barrier, as evidenced by the presence of gadolinium-enhancing lesions on MRI, results from infiltration of inflammatory cells into the CNS. The relationship between inflammation and damage to the blood-brain barrier is less obvious in SPMS and PPMS, because impairment can occur with or without inflammatory infiltrates. Features of lymphoid follicle are found in large aggregates of inflammatory cells observed in the meninges. As the disease progresses, inflammation becomes compartmentalized behind the intact blood-brain barrier. Demyelination. During all stages of MS, plaques may be found in the gray and white matter. In progressive MS, slow expansion of preexisting lesions results in pronounced cortical demyelination associated with extensive diffuse injury T H E N E U R O L O G Y R E P O R T S u m m e r
7 in white and gray matter that appears to be normal. Cortical lesions occur most abundantly during the progressive stage of MS; these lesions are most prominent in subpial cortical layers, and they can be linked to local meningeal inflammation. Finally, activated microglia are associated with active lesions. The pathology of acute and relapsing MS is dominated by focal inflammatory demyelinated plaques in the white matter. Tissue injury. The brains of patients with MS exhibit widespread inflammation, microglial activation, astrogliosis, and mild demyelination and axonal loss in normal-appearing white matter. The extent and severity of these changes increase with disease duration and most closely are asociated with progressive MS; small-caliber axons are most affected. However, the extent of diffuse injury does not correlate with the number, size, or destructiveness of focal lesions. Instead, it correlates moderately with the extent of cortical demyelination. RRMS is related to distinct patterns of demyelination and tissue injury, probably because of distinct immune processes of inflammatory lesions. In contrast, patterns of tissue injury largely are homogeneous in SPMS and PPMS, probably because of the slow expansion of existing lesions with sparse remyelination. Disease Mechanisms Microglial activation. In both RRMS and progressive MS, active tissue injury is associated with microglial activation. In addition, microglial nodules are seen in progressive MS. Oxidative bursts by activated microglia my help to induce demyelination and progressive axonal injury. Microglia may be neuroprotective and could promote remyelination after debris is removed and neurotrophic molecules are secreted. Mitochondrial injury. The pathogenesis of MS may be related to energy deficiency or virtual hypoxia. Impaired NADH dehydrogenase activity and increases in complex IV activity have been noted in the mitochondria of MS lesions. Mitochondrial injury may reflex oxidative damage noted in areas of initial tissue injury. The increased susceptibility to neurodegeneration seen in patients with SPMS and PPMS may be explained partially by an accumulation of mitochondrial DNA deletions. Oxidative stress encourages mitochondrial dysfunction in a number of ways. Free radicals disrupt mitochondrial enzyme function. Oxidative stress modifies mitochondrial proteins and accelerates their degeneration. Further, it interferes with de novo synthesis of respiratory chain components and induces mitochondrial DNA damage. Oxidative injury is pronounced in progressive MS lesions, even though inflammation is low; therefore, it may be driven by factors other than inflammatory processes. Iron accumulation. Iron accumulates in the aging brain and is stored in oligodendrocytes; subsequently, it is detoxified when it binds to ferritin. Intracytoplasmic iron accumulation may explain why these cells are so susceptible to degeneration during oxidative stress. In MS lesions, activated macrophages and microglia take up iron, leading to dystrophy, fragmentation, and cellular degeneration. The process depends upon patient age and may be more pronounced among patients with progressive MS than among those with RRMS. Summary More information is needed about the disease mechanisms of RRMS and progressive MS. A number of interlinked pathways contribute to the development of the disease, and inflammation mediated by T and B cells and macrophages orchestrate demyelination and degeneration in patients with all forms of MS. In progressive forms of the disease, inflammation is noted by lymphoid follicles in meninges becoming trapped behind an intact blood-brain barrier, making use of anti-inflammatory agents ineffectual. Tissue injury may be affected by microglia activation, oxidative injury, and damage to mitochondria. In progressive MS, liberation of iron may enhance oxidative damage and result in increased neurodegeneration. Accumulated tissue damage exhausts the functional reserve capacity of the brain and may accelerate clinical deterioration, with slow, progressive tissue injury. Better models of progressive MS are needed to develop effective DMTs for it. SUGGESTED READINGS Abbas A, Lichtman A (eds). Basic Immunology, Functions and Disorders of the Immune System. 3rd ed. Philadelphia PA: Saunders Elsevier; Calabresi PA, Kieseier B, Arnold D, et al; ADVANCE Study Investigators. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014;13: Clinical Immunology Society. Basic immunology. educational-resources/basic-immunology. Accessed July 17, Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380: Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380: Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology. 2002;58(suppl 4):S3 S9. Giovannoni G, Gold R, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurol. 2014;13: Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo controlled trial. Lancet. 2013;381: Heath G. Basic immunology. ec6326f4b524b41c_heath pdf. Accessed July 17, Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378: Lalive PH, Neuhaus O, Benkhoucha MS, et al. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs. 201;25: Mendes A, Sá JM. Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works. Arquivos de Neuro-Psiquiatria. 2011;69: O Connor PW, Oh J. Disease-modifying agents in multiple sclerosis. Handb Clin Neurol. 2014;122: Oh J, Saidha S, Cortese I, et al. Daclizumabinduced adverse events in multiple organ systems in multiple sclerosis. Neurology. 2014;82: The immune system in health and disease. In: Janeway CA, Travers P, Walport M, Shlomchik MJ. Immunobiology. 5 th ed. New York, NY: Garland Science; T H E N E U R O L O G Y R E P O R T V o l u m e 7 N u m b e r 2
Pediatric MS treatments: What do you start with, when do you switch?
Pediatric MS treatments: What do you start with, when do you switch? Tim Lotze, M.D. Associate Professor of Pediatric Neurology Texas Children s Hospital Baylor College of Medicine Disclosures Clinical
More informationBiologics and Beyond: Treatment of Multiple Sclerosis. Rita Jebrin, PharmD, BCPS
Biologics and Beyond: Treatment of Multiple Sclerosis Rita Jebrin, PharmD, BCPS Disclosure Information Biologics and Beyond: Treatment of Multiple Sclerosis Rita Jebrin, PharmD, BCPS I have no financial
More informationMitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA Disclosures Consultant and Speaker Bureau member for Biogen-Idec, Pfizer, TEVA Neuroscience, Bayer, EMD Serrono, Questcor, Novartis,
More informationMULTIPLE SCLEROSIS - REVIEW AND UPDATE
MULTIPLE SCLEROSIS - REVIEW AND UPDATE Luka Vlahovic, MD Neuroimmunology/Multiple Sclerosis Creighton University Medical Center MS is primary demyelinating disease of the central nervous system. MS is
More informationProgress in MS: Current and Emerging Therapies. Presented by: Dr. Kathryn Giles, MD MSc FRCPC Cambridge, Ontario, Canada
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC Cambridge, Ontario, Canada Today s Discussion Natural History and Classification of MS Treating MS Management
More informationDefense mechanism against pathogens
Defense mechanism against pathogens Immune System What is immune system? Cells and organs within an animal s body that contribute to immune defenses against pathogens ( ) Bacteria -Major entry points ;open
More informationMedication Policy Manual. Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 16, 2016 Next Review Date: December 2017 Effective Date: January
More informationThe Immune System. These are classified as the Innate and Adaptive Immune Responses. Innate Immunity
The Immune System Biological mechanisms that defend an organism must be 1. triggered by a stimulus upon injury or pathogen attack 2. able to counteract the injury or invasion 3. able to recognise foreign
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 16, 2016 Next Review Date: December 2017 Effective Date: January
More informationImmune System AP SBI4UP
Immune System AP SBI4UP TYPES OF IMMUNITY INNATE IMMUNITY ACQUIRED IMMUNITY EXTERNAL DEFENCES INTERNAL DEFENCES HUMORAL RESPONSE Skin Phagocytic Cells CELL- MEDIATED RESPONSE Mucus layer Antimicrobial
More informationTREATING MULTIPLE SCLEROSIS The Current Disease Modifying Therapies Beverly Gilder, M.D. Blue Sky Neurology MS Center
TREATING MULTIPLE SCLEROSIS 2018 The Current Disease Modifying Therapies Beverly Gilder, M.D. Blue Sky Neurology MS Center Welcome Thank you for joining us! Today you will learn about MS treatment choices
More informationImmunology for the Rheumatologist
Immunology for the Rheumatologist Rheumatologists frequently deal with the immune system gone awry, rarely studying normal immunology. This program is an overview and discussion of the function of the
More informationChapter 13 Lymphatic and Immune Systems
The Chapter 13 Lymphatic and Immune Systems 1 The Lymphatic Vessels Lymphoid Organs Three functions contribute to homeostasis 1. Return excess tissue fluid to the bloodstream 2. Help defend the body against
More informationChapter 24 The Immune System
Chapter 24 The Immune System The Immune System Layered defense system The skin and chemical barriers The innate and adaptive immune systems Immunity The body s ability to recognize and destroy specific
More informationOverview of the Lymphoid System
Overview of the Lymphoid System The Lymphoid System Protects us against disease Lymphoid system cells respond to Environmental pathogens Toxins Abnormal body cells, such as cancers Overview of the Lymphoid
More informationI. Lines of Defense Pathogen: Table 1: Types of Immune Mechanisms. Table 2: Innate Immunity: First Lines of Defense
I. Lines of Defense Pathogen: Table 1: Types of Immune Mechanisms Table 2: Innate Immunity: First Lines of Defense Innate Immunity involves nonspecific physical & chemical barriers that are adapted for
More informationMedical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University
Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve
More informationBody Defense Mechanisms
BIOLOGY OF HUMANS Concepts, Applications, and Issues Fifth Edition Judith Goodenough Betty McGuire 13 Body Defense Mechanisms Lecture Presentation Anne Gasc Hawaii Pacific University and University of
More informationChapter 17. The Lymphatic System and Immunity. Copyright 2010, John Wiley & Sons, Inc.
Chapter 17 The Lymphatic System and Immunity Immunity Innate Immunity Fast, non-specific and no memory Barriers, ph extremes, Phagocytes & NK cells, fever, inflammation, complement, interferon Adaptive
More informationAll animals have innate immunity, a defense active immediately upon infection Vertebrates also have adaptive immunity
1 2 3 4 5 6 7 8 9 The Immune System All animals have innate immunity, a defense active immediately upon infection Vertebrates also have adaptive immunity Figure 43.2 In innate immunity, recognition and
More informationLe Hua, MD. Disclosures Teaching and Speaking: Teva Neurosciences, Genzyme, Novartis Advisory Board: Genzyme, EMD Serono
Le Hua, MD Le Hua, MD, is a staff neurologist at Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, NV. She is involved in clinical trials assessing new therapies for the treatment of MS and
More informationChapter 22: The Lymphatic System and Immunity
Bio40C schedule Lecture Immune system Lab Quiz 2 this week; bring a scantron! Study guide on my website (see lab assignments) Extra credit Critical thinking questions at end of chapters 5 pts/chapter Due
More informationDemyelinating Diseases: Multiple Sclerosis January 10, 2018 Dr. Ostrow
Demyelinating Diseases: Multiple Sclerosis January 10, 2018 Dr. Ostrow Reading: Robbins & Cotran, 9 th edition, pp 1283-1286 Robbins Basic Pathology, 9 th edition, 832-835 Overview: Grossly, myelin is
More informationTopics in Parasitology BLY Vertebrate Immune System
Topics in Parasitology BLY 533-2008 Vertebrate Immune System V. Vertebrate Immune System A. Non-specific defenses against pathogens 1. Skin - physical barrier a. Tough armor protein KERATIN b. Surface
More informationNOTES: CH 43, part 1 The Immune System - Nonspecific & Specific Defenses ( )
NOTES: CH 43, part 1 The Immune System - Nonspecific & Specific Defenses (43.1-43.2) The lymphatic system is closely associated with the cardiovascular system. LYMPHATIC PATHWAYS Lymphatic capillaries
More informationWhite Blood Cells (WBCs)
YOUR ACTIVE IMMUNE DEFENSES 1 ADAPTIVE IMMUNE RESPONSE 2! Innate Immunity - invariant (generalized) - early, limited specificity - the first line of defense 1. Barriers - skin, tears 2. Phagocytes - neutrophils,
More informationWelcome to todays Webinar
Welcome to todays Webinar Your Presenter is: Lyndal Emery Your Facilitator is: Andrea Salmon Acknowledgement We acknowledge and pay respect to the traditional custodians past and present on whose lands
More informationImmune System. Biol 105 Chapter 13
Immune System Biol 105 Chapter 13 Outline Immune System I. Function of the Immune system II. Barrier Defenses III. Nonspecific Defenses A. Immune system cells B. Inflammatory response C. Complementary
More informationInnate Immunity. Bởi: OpenStaxCollege
Innate Immunity Bởi: OpenStaxCollege The vertebrate, including human, immune system is a complex multilayered system for defending against external and internal threats to the integrity of the body. The
More informationThird line of Defense
Chapter 15 Specific Immunity and Immunization Topics -3 rd of Defense - B cells - T cells - Specific Immunities Third line of Defense Specific immunity is a complex interaction of immune cells (leukocytes)
More informationCampbell's Biology: Concepts and Connections, 7e (Reece et al.) Chapter 24 The Immune System Multiple-Choice Questions
Campbell's Biology: Concepts and Connections, 7e (Reece et al.) Chapter 24 The Immune System 24.1 Multiple-Choice Questions 1) The body's innate defenses against infection include A) several nonspecific
More informationAdvances in the Management of Multiple Sclerosis: A closer look at novel therapies. Disclosures
Advances in the Management of Multiple Sclerosis: A closer look at novel therapies Lily Jung Henson, MD, MMM, FAAN Chief of Neurology Piedmont Healthcare, Atlanta, GA National Association of Managed Care
More information11/25/2017. THE IMMUNE SYSTEM Chapter 43 IMMUNITY INNATE IMMUNITY EXAMPLE IN INSECTS BARRIER DEFENSES INNATE IMMUNITY OF VERTEBRATES
THE IMMUNE SYSTEM Chapter 43 IMMUNITY INNATE IMMUNITY EXAMPLE IN INSECTS Exoskeleton made of chitin forms the first barrier to pathogens Digestive system is protected by a chitin-based barrier and lysozyme,
More informationThe Adaptive Immune Responses
The Adaptive Immune Responses The two arms of the immune responses are; 1) the cell mediated, and 2) the humoral responses. In this chapter we will discuss the two responses in detail and we will start
More informationPhysiology Unit 3. ADAPTIVE IMMUNITY The Specific Immune Response
Physiology Unit 3 ADAPTIVE IMMUNITY The Specific Immune Response In Physiology Today The Adaptive Arm of the Immune System Specific Immune Response Internal defense against a specific pathogen Acquired
More informationFluid movement in capillaries. Not all fluid is reclaimed at the venous end of the capillaries; that is the job of the lymphatic system
Capillary exchange Fluid movement in capillaries Not all fluid is reclaimed at the venous end of the capillaries; that is the job of the lymphatic system Lymphatic vessels Lymphatic capillaries permeate
More informationACTIVATION OF T LYMPHOCYTES AND CELL MEDIATED IMMUNITY
ACTIVATION OF T LYMPHOCYTES AND CELL MEDIATED IMMUNITY The recognition of specific antigen by naïve T cell induces its own activation and effector phases. T helper cells recognize peptide antigens through
More informationThere are 2 major lines of defense: Non-specific (Innate Immunity) and. Specific. (Adaptive Immunity) Photo of macrophage cell
There are 2 major lines of defense: Non-specific (Innate Immunity) and Specific (Adaptive Immunity) Photo of macrophage cell Development of the Immune System ery pl neu mφ nk CD8 + CTL CD4 + thy TH1 mye
More informationImmune System. Biol 105 Lecture 16 Chapter 13
Immune System Biol 105 Lecture 16 Chapter 13 Outline Immune System I. Function of the Immune system II. Barrier Defenses III. Nonspecific Defenses A. Immune system cells B. Inflammatory response C. Complementary
More informationNEUROLOGY UPDATE IV: MULTIPLE SCLEROSIS
NEUROLOGY UPDATE IV: MULTIPLE SCLEROSIS Learning Objectives Daniel Harrison, MD University of Maryland School of Medicine Baltimore, MD Upon completion of this module, participants should be familiar with:
More informationWelcome to today s webinar: Learn about MS
Welcome to today s webinar: Learn about MS Your Presenter is Dr Todd Hardy Your Facilitator is Belinda Saunders Housekeeping Thanks for joining us for this webinar welcome! You will be able to: hear the
More informationChapter 21: Innate and Adaptive Body Defenses
Chapter 21: Innate and Adaptive Body Defenses I. 2 main types of body defenses A. Innate (nonspecific) defense: not to a specific microorganism or substance B. Adaptive (specific) defense: immunity to
More informationInternal Defense Notes
Internal environment of animals provides attractive area for growth of bacteria, viruses, fungi Harm via: 1. destruction of cells 2. production of toxic chemicals To protect against foreign invaders, humans
More informationAutoimmune Diseases. Betsy Kirchner CNP The Cleveland Clinic
Autoimmune Diseases Betsy Kirchner CNP The Cleveland Clinic Disclosures (financial) No relevant disclosures Learning Objectives Explain the pathophysiology of autoimmune disease Discuss safe administration
More informationImmune System. Biology 105 Lecture 16 Chapter 13
Immune System Biology 105 Lecture 16 Chapter 13 Outline: Immune System I. Functions of the immune system II. Barrier defenses III. Non-specific defenses A. Immune system cells B. Inflammatory response
More informationThird line of Defense. Topic 8 Specific Immunity (adaptive) (18) 3 rd Line = Prophylaxis via Immunization!
Topic 8 Specific Immunity (adaptive) (18) Topics - 3 rd Line of Defense - B cells - T cells - Specific Immunities 1 3 rd Line = Prophylaxis via Immunization! (a) A painting of Edward Jenner depicts a cow
More informationINNATE IMMUNITY Non-Specific Immune Response. Physiology Unit 3
INNATE IMMUNITY Non-Specific Immune Response Physiology Unit 3 Protection Against Infection The body has several defenses to protect itself from getting an infection Skin Mucus membranes Serous membranes
More informationThe Immune System: Innate and Adaptive Body Defenses Outline PART 1: INNATE DEFENSES 21.1 Surface barriers act as the first line of defense to keep
The Immune System: Innate and Adaptive Body Defenses Outline PART 1: INNATE DEFENSES 21.1 Surface barriers act as the first line of defense to keep invaders out of the body (pp. 772 773; Fig. 21.1; Table
More informationOverview. Barriers help animals defend against many dangerous pathogens they encounter.
Immunity Overview Barriers help animals defend against many dangerous pathogens they encounter. The immune system recognizes foreign bodies and responds with the production of immune cells and proteins.
More informationI. Critical Vocabulary
I. Critical Vocabulary A. Immune System: a set of glands, tissues, cells, and dissolved proteins that combine to defend against non-self entities B. Antigen: any non-self chemical that triggers an immune
More informationNonspecific External Barriers skin, mucous membranes
Immune system Chapter 36 BI 103 Plant-Animal A&P Levels of Defense Against Disease Nonspecific External Barriers skin, mucous membranes Physical barriers? Brainstorm with a partner If these barriers are
More informationchapter 17: specific/adaptable defenses of the host: the immune response
chapter 17: specific/adaptable defenses of the host: the immune response defense against infection & illness body defenses innate/ non-specific adaptable/ specific epithelium, fever, inflammation, complement,
More informationImmunity and Infection. Chapter 17
Immunity and Infection Chapter 17 The Chain of Infection Transmitted through a chain of infection (six links) Pathogen: Disease causing microorganism Reservoir: Natural environment of the pathogen Portal
More informationChapter 1. Chapter 1 Concepts. MCMP422 Immunology and Biologics Immunology is important personally and professionally!
MCMP422 Immunology and Biologics Immunology is important personally and professionally! Learn the language - use the glossary and index RNR - Reading, Note taking, Reviewing All materials in Chapters 1-3
More informationUnderstanding basic immunology. Dr Mary Nowlan
Understanding basic immunology Dr Mary Nowlan 1 Immunology Immunology the study of how the body fights disease and infection Immunity State of being able to resist a particular infection or toxin 2 Overview
More informationTitle: NATURAL KILLER CELL FUNCTIONS AND SURFACE RECEPTORS
LECTURE: 14 Title: NATURAL KILLER CELL FUNCTIONS AND SURFACE RECEPTORS LEARNING OBJECTIVES: The student should be able to: Describe the general morphology of the NK-cells. Enumerate the different functions
More informationGet on with life, we ll see you. in 6 months. Living your life your way with MS
Get on with life, we ll see you in 6 months. Living your life your way with MS If you re one of the 4000 New Zealanders affected by MS, ask your doctor or nurse if OCREVUS is right for you. Contents What
More informationUnit 5 The Human Immune Response to Infection
Unit 5 The Human Immune Response to Infection Unit 5-page 1 FOM Chapter 21 Resistance and the Immune System: Innate Immunity Preview: In Chapter 21, we will learn about the branch of the immune system
More informationThe Lymphatic System and Immunity. Chapters 20 & 21
The Lymphatic System and Immunity Chapters 20 & 21 Objectives 1. SC.912.L.14.52 - Explain the basic functions of the human immune system, including specific and nonspecific immune response, vaccines, and
More informationOpenStax-CNX module: m Innate Immunity. OpenStax College. Abstract
OpenStax-CNX module: m45542 1 Innate Immunity OpenStax College This work is produced by OpenStax-CNX and licensed under the Creative Commons Attribution License 3.0 By the end of this section, you will
More informationAcquired Immunity Cells are initially and require before they can work Responds to individual microbes
1 of 10 THE IMMUNE SYSTEM CHAPTER 43; PAGES 898 921 WHY DO WE NEED AN IMMUNE SYSTEM? It s a dirty, dirty world out there and we are vastly outnumbered Bacteria and parasites are everywhere The body has
More informationBlood and Immune system Acquired Immunity
Blood and Immune system Acquired Immunity Immunity Acquired (Adaptive) Immunity Defensive mechanisms include : 1) Innate immunity (Natural or Non specific) 2) Acquired immunity (Adaptive or Specific) Cell-mediated
More informationPer Soelberg Sørensen
Per Soelberg Sørensen Danish Multiple Sclerosis Center Department of Neurology Rigshospitalet, University of Copenhagen Copenhagen, Denmark Declared receipt personal compensation for serving on scientific
More informationCELL BIOLOGY - CLUTCH CH THE IMMUNE SYSTEM.
!! www.clutchprep.com CONCEPT: OVERVIEW OF HOST DEFENSES The human body contains three lines of against infectious agents (pathogens) 1. Mechanical and chemical boundaries (part of the innate immune system)
More informationAP Biology. Why an immune system? Chapter 43. Immune System. Lines of defense. 1st: External defense. 2nd: Internal, broad range patrol
Chapter 43. Immune System lymphocytes attacking cancer cell lymph phagocytic leukocyte Why an immune system? Attack from outside lots of organisms want you for lunch! animals must defend themselves against
More informationWarm-up. Parts of the Immune system. Disease transmission. Disease transmission. Why an immune system? Chapter 43 3/9/2012.
Warm-up Objective: Explain how antigens react with specific lymphocytes to induce immune response and immunological memory. Warm-up: Which of the following would normally contain blood with the least amount
More informationAntigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS
1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family
More informationCellular Pathology of immunological disorders
Cellular Pathology of immunological disorders SCBM344 Cellular and Molecular Pathology Witchuda Payuhakrit, Ph.D (Pathobiology) witchuda.pay@mahidol.ac.th Objectives Describe the etiology of immunological
More informationChapter 38- Immune System
Chapter 38- Immune System First Line of Defense: Barriers Nonspecific defenses, such as the skin and mucous membranes, are barriers to potential pathogens. In addition to being a physical barrier to pathogens,
More informationHow the Innate Immune System Profiles Pathogens
How the Innate Immune System Profiles Pathogens Receptors on macrophages, neutrophils, dendritic cells for bacteria and viruses Broad specificity - Two main groups of bacteria: gram positive, gram-negative
More informationDisease causing organisms Resistance Immunity
Part 1 Disease causing organisms Resistance Immunity Bacteria Most common pathogens Anthrax Cholera Staphylococcus epidermidis bacteria Bacterial diseases Tuberculosis Cholera Bubonic Plague Tetanus Effects
More informationAdaptive immune responses: T cell-mediated immunity
MICR2209 Adaptive immune responses: T cell-mediated immunity Dr Allison Imrie allison.imrie@uwa.edu.au 1 Synopsis: In this lecture we will discuss the T-cell mediated immune response, how it is activated,
More informationLYMPHATIC AND IMMUNE SYSTEMS. Chapter 33
LYMPHATIC AND IMMUNE SYSTEMS Chapter 33 THE LYMPHATIC SYSTEM The lymphatic system has three main functions Take up excess tissue fluid and return it to the bloodstream Receive fats called lipoproteins
More informationImmune System. Presented by Kazzandra Anton, Rhea Chung, Lea Sado, and Raymond Tanaka
Immune System Presented by Kazzandra Anton, Rhea Chung, Lea Sado, and Raymond Tanaka Content Standards 35.1 In innate immunity, recognition and response rely on traits common to groups of pathogens 35.2
More informationThe Immune System. Protective system that fight disease in the body. Includes parts of the circulatory system and lymph system.
The Immune System Protective system that fight disease in the body. Includes parts of the circulatory system and lymph system. The immune system recognizes, attacks, destroys, and remembers each kind of
More informationKristen Helms, PharmD Clinical Associate Professor Department of Pharmacy Practice and Office of Teaching, Learning and Assessment Auburn University
Kristen Helms, PharmD Clinical Associate Professor Department of Pharmacy Practice and Office of Teaching, Learning and Assessment Auburn University Harrison School of Pharmacy Auburn, Alabama Presenter:
More informationNeurodegeneration and macrophages; a beneficial or harmful role for macrophages and microglia in neuronal damage during multiple sclerosis
Neurodegeneration and macrophages; a beneficial or harmful role for macrophages and microglia in neuronal damage during multiple sclerosis Marlijn van der Poel Writing assignment: literature review October
More informationProperties & Overview of IRs Dr. Nasser M. Kaplan JUST, Jordan. 10-Jul-16 NM Kaplan 1
Properties & Overview of IRs Dr. Nasser M. Kaplan JUST, Jordan 10-Jul-16 NM Kaplan 1 Major components of IS & their properties Definitions IS = cells & molecules responsible for: 1- Physiologic; protective
More informationANATOMY OF THE IMMUNE SYSTEM
Immunity Learning objectives Explain what triggers an immune response and where in the body the immune response occurs. Understand how the immune system handles exogenous and endogenous antigen differently.
More informationDiseases-causing agents, pathogens, can produce infections within the body.
BIO 212: ANATOMY & PHYSIOLOGY II 1 CHAPTER 16 Lecture: Dr. Lawrence G. Altman www.lawrencegaltman.com Some illustrations are courtesy of McGraw-Hill. LYMPHATIC and IMMUNE Systems Body Defenses Against
More informationImmunity. Chapter 38 Part 1
Immunity Chapter 38 Part 1 Impacts, Issues Frankie s Last Wish Infection with a common, sexually transmitted virus (HPV) causes most cervical cancers including the one that killed Frankie McCullogh 38.1
More informationLymphatic System & Immunity
Lymphatic System & Immunity Arteriole Venule Tissue Blood Lymph cells capilla capillaries ries Lymphatic System -closely related to cardiovascular system -conducting system that carries fluid from extracellular
More information2014 Pearson Education, Inc. Exposure to pathogens naturally activates the immune system. Takes days to be effective Pearson Education, Inc.
The innate immune interact with the adaptive immune system 1. Damage to skin causes bleeding = bradykinin activated, resulting in inflammation 2. Dendritic phagocytose pathogens Adaptive immunity 4. Dendritic
More informationChapter 23 Immunity Exam Study Questions
Chapter 23 Immunity Exam Study Questions 1. Define 1) Immunity 2) Neutrophils 3) Macrophage 4) Epitopes 5) Interferon 6) Complement system 7) Histamine 8) Mast cells 9) Antigen 10) Antigens receptors 11)
More informationMicrobiology 204: Cellular and Molecular Immunology
Microbiology 204: Cellular and Molecular Immunology Class meets MWF 1:00-2:30PM (*exceptions: no class Fri Sept 23, Fri Oct 14, Nov 11, or Wed Nov 23) Lectures are open to auditors and will be live-streamed
More informationWHY IS THIS IMPORTANT?
CHAPTER 16 THE ADAPTIVE IMMUNE RESPONSE WHY IS THIS IMPORTANT? The adaptive immune system protects us from many infections The adaptive immune system has memory so we are not infected by the same pathogen
More informationMOLECULAR IMMUNOLOGY Manipulation of immune response Autoimmune diseases & the pathogenic mechanism
MOLECULAR IMMUNOLOGY Manipulation of immune response Autoimmune diseases & the pathogenic mechanism SCHMAIEL SHIRDEL CONTENT 2 Introduction Autoimmune diseases Classification Involved components Autoimmune
More informationPotential Rebalancing of the Immune System by Anti-CD52 Therapy
Potential Rebalancing of the Immune System by Anti-CD52 Therapy Johanne Kaplan, PhD VP Neuroimmunology Research Genzyme March 26, 2013 RESTRICTED USE SEE TRAINING MEMO 2011 DO Genzyme NOT 1COPY Corporation
More informationCarolyn Taylor, M.D. Swedish Neuroscience Center
Carolyn Taylor, M.D. Swedish Neuroscience Center When should disease modifying therapy be discontinued in MS? Should we be using aggressive treatments earlier in the MS disease course and reserving the
More informationChoices. Disease modifying treatments. Read me
Choices Disease modifying treatments Read me Disease modifying treatments Disease modifying therapies (DMTs) are medications which modify the course of multiple sclerosis (MS) and are designed to reduce
More informationLecture 10 Immune System
Lecture 10 Immune System Lecture 10 1. Introduction 2. Nonspecific External Defenses 3. Innate Immune Response 4. Acquired Immune Response 5. Antibiotics and Vaccines 1 The not-so-common cold A cold is
More informationPathophysiologic Basis of Autoimmune Disorders
Pathophysiologic Basis of Autoimmune Disorders Linda Felver, Ph.D., R.N. Associate Professor School of Nursing Oregon Health & Science University The immune system has two arms: Adaptive (Acquired) Immune
More informationCH. 24. The Immune System
CH. 24 The Immune System The immune systems consists of organs, cells, and molecules that fight infections and protect us from invaders. Pathogens: Bacteria, Viruses, Parasites, Fungi 1. Innate (nonspecific)
More informationThe Immune System All animals have innate immunity, a defense active immediately
The Immune System All animals have innate immunity, a defense active immediately upon infection Vertebrates also have adaptive immunity Figure 43.2 INNATE IMMUNITY (all animals) Recognition of traits shared
More informationIntroduction to Immune System
Introduction to Immune System Learning outcome You will be able to understand, at a fundamental level, the STRUCTURES and FUNCTIONS of cell surface and soluble molecules involved in recognition of foreign
More informationPharmacotherapy Update Multiple Sclerosis
Pharmacotherapy Update Multiple Sclerosis Yolande Hanssens SIG Leader Medicine Information Hamad Medical Corporation Pharmacy Department - Clinical Service Unit Doha - Qatar Heidelberg/October 2017 Pharmacotherapy
More informationImmunobiology 7. The Humoral Immune Response
Janeway Murphy Travers Walport Immunobiology 7 Chapter 9 The Humoral Immune Response Copyright Garland Science 2008 Tim Worbs Institute of Immunology Hannover Medical School 1 The course of a typical antibody
More informationMEDIA BACKGROUNDER. Multiple Sclerosis: A serious and unpredictable neurological disease
MEDIA BACKGROUNDER Multiple Sclerosis: A serious and unpredictable neurological disease Multiple sclerosis (MS) is a complex chronic inflammatory disease of the central nervous system (CNS) that still
More informationAttribution: University of Michigan Medical School, Department of Microbiology and Immunology
Attribution: University of Michigan Medical School, Department of Microbiology and Immunology License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution
More information